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ABSTRACT
Bronchial asthma has been recognized as an inflam-
matory disorder in this past decade. This leads to an
assumption that perfect control of inflammatory cells
may cure this disease. However, herein we report 
on an asthmatic whose airway hyperresponsiveness
(AHR) did not change after bone marrow transplanta-
tion (BMT). The concentrations of acetylcholine to
produce a 20% fall in forced expiratory volume in 1 s
15 days before and 98 days after BMT were 900 and
480 µg/mL, respectively. Asthma treatment with beclo-
methasone dipropionate and theophylline was con-
tinued before and after BMT and a conventional
supporting therapy for BMT with cyclosporine A and
methylprednisolone, followed by oral administration
of tacrolimus hydrate alone inhibited graft-versus-host
disease. Plasma interleukin (IL)-4, IL-5 and IgE, but not
interferon-γ, levels decreased after BMT. Note that the
second measurement of airway sensitivity was per-
formed under systemic administration of tacrolimus.
The presented case suggests that replacement of bone
marrow-derived inflammatory cells is not enough 
to reverse once-established AHR. Hence, AHR and
airway inflammation may develop independently in
some part, but both need to be present for asthma to
be present in this asthmatic.
Key words: airway hyperresponsiveness, beclo-
methasone dipropionate, bone marrow transplanta-
tion, graft-versus-host disease, peak expiratory flow.
INTRODUCTION
Asthma has been recognized as an inflammatory dis-
order in this past decade.1,2 Indeed, inhaled cortico-
steroids have revolutionized the treatment of asthma.3
However, airway hyperresponsiveness (AHR) often per-
sists, even after prolonged corticosteroid therapy.2,4 It is
not known whether this is caused by incomplete control of
inflammatory cells or not. Herein we report on an asth-
matic whose AHR did not change after total replacement
of hematopoietic cells by bone marrow transplantation
(BMT).
CLINICAL SUMMARY
A 49-year-old man was referred to Saiseikai Maebashi
Hospital in December 1998 for treatment of acute mye-
loid leukemia (myelomonocytic leukemia, M4) by BMT.
Over the previous 2 years, he had complained of recur-
rent nocturnal dyspnea and wheezing. His pulmonary
functions revealed an obstructive pattern despite no his-
tory of smoking. Salbutamol sulfate inhalation (200 µg)
increased forced expiratory volume in 1 s (FEV1) from
1.68 to 2.23 L (a 32% increase). His plasma IgE level,
detected by a radioimmunosorbent test, was 150 IU/mL
and he showed no reaction to the 16 common allergens
by a radioallergosorbent test. The patient was treated with
theophylline (200 mg twice daily) and salbutamol inhala-
tion on demand, daily variability in peak expiratory flow
(PEF) was more than 20%. Beclomethasone dipropionate
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(BDP) inhalation (400 µg twice daily) improved his symp-
toms, increasing his morning PEF from approximately
350 to 430 L/min and decreasing his PEF variability.
We diagnosed his case as non-atopic asthma and not
chronic obstructive lung disease. We measured his air-
way sensitivity to acetylcholine using the standard method
of the Japanese Society of Allergology5 before and 
3 months after BMT. Plasma IgE levels and cytokines were
also measured before and after BMT.
A successful BMT was performed in June 1999. The
donor was his sister, who had neither an allergic history
nor any respiratory symptoms associated with asthma.
The chromatin pattern of bone marrow changed from
46,XY to 46,XX after BMT (Fig. 1). We analyzed 500 cells
from the bone marrow on day 47 with fluorescence in situ
hybridization. All cells revealed XX signaling (100%),
whereas the control cells from a healthy male subject
showed XY signaling (96.8%).
Conventional supporting therapy for BMT was started:
cyclosporine A (75–400 mg/day) and methylpredni-
solone (40–125 mg/day) were administered from day –1
to day 31, followed by oral administration of tacrolimus
hydrate (2 mg/day) alone. Mean (±SD) plasma concen-
trations of cyclosporine A and tacrolimus were 264 ± 20
and 13.2 ± 1.9 ng/mL, respectively. Asthma treatment
(BDP and theophylline) was also continued after BMT.
From day 48 to day 53, the patient complained of
dyspnea with a decrease in PEF to 300 L/min, fever up,
abdominal pain and diarrhea. Because acute graft-
versus-host disease (GVHD) in the gastrointestinal tract
was suspected, we injected methylprednisolone to the
patient. As a result, the symptoms disappeared within 
1 week. Because PEF measurement is effort dependent,
evaluation of the low PEF value was practically difficult
under such conditions. Thus, we cannot discriminate the
decreased PEF from a GVHD-associated asthma attack.
Except for this episode, there was no typical asthma
attack after BMT. The second measurement of airway
sensitivity was performed on day 98 under systemic
administration of tacrolimus. As shown in Table 1, 
AHR was not changed by BMT. We did not observe 
any remarkable findings (e.g. consolidation, interstitial
changes, granular opacities) in computed tomography
images of the lungs before and after BMT. The patient
was discharged in October 1999.
However, in November 1999, because of dyspnea
and fever up, the patient was readmitted to Saiseikai
Maebashi Hospital. Despite intensive treatment with anti-
biotics, including meropenem trihydrate, he died from
Pseudomonas aeruginosa pneumonia. We verified neither
leukemia relapse nor obliterative bronchiolitis at autopsy.
It was difficult to evaluate mild airway remodeling associ-
ated with asthma, because severe respiratory infection
damaged the airway (Fig. 2).
DISCUSSION
To our knowledge, this is the first case of an asthmatic
whose AHR did not change after total replacement of
hematopoietic cells. Before and after BMT, a comparable
good responses to salbutamol inhalation and no remark-
able findings in computed tomography images of the
lungs indicate that airflow limitation in this patient was
reversible and that the unchanged AHR was not due to
Fig. 1 Chromatin analysis before and after bone marrow transplantation (BMT). The chromatin analysis patterns of the bone
marrow before and 12 days after BMT are 46,XY (a) and 46,XX (b).
obliterative bronchiolitis. This was verified histologically
at autopsy. Obliterative bronchiolitis after BMT is caused
by GVHD and airflow limitation is usually progressive and
irreversible. Thus, obliterative bronchiolitis is not respon-
sible for airflow limitation after BMT.
Alveolar macrophages are completely replaced by
donor-derived cells within 90 days after BMT in humans.6
Peripheral blood monocytes are precursors of alveolar
macrophages and a continuous influx of monocytes 
to the lung is responsible for maintaining alveolar
macrophage numbers. Recently, however, the kinetics of
alveolar macrophages have been demonstrated after
allogeneic BMT.7 The proliferation of alveolar macro-
phages in situ may contribute to reconstitution of the
alveolar macrophage population 50 days after BMT.
More importantly, DNA fingerprint analysis reveals that,
on day 83, the donor bands predominate but the recipi-
ent genotype is still seen.7 This suggests that the minority
of alveolar macrophages may be of recipient origin on
day 98 in this asthmatic. Another important population
for antigen presentation in the lung is the dendritic cell.
Airway dendritic cells are recruited from bone marrow 
to the mucosa, reside for a few days and then move to 
the regional lymph nodes in animals.8 The kinetics of
dendritic cells are unknown after BMT in humans. One
possible hypothesis is that the resident (recipient) antigen-
presenting cells, including alveolar macrophages and
dendritic cells, may interact with newly transplanted
bone marrow (donor), trigger reconstitution of the Th2
cytokine-predominant immune system (chimera) and
maintain AHR. However, the plasma cytokine profile after
BMT in the present patient suggests that the imbalance
between Th1 and Th2 cells was restored, at least in part,
with BMT (Table 1). Thus, the reconstitution hypothesis is
not reasonable for the unchanged AHR.
We wished to estimate the Th2-mediated immune
response through the interleukin (IL)-4/IgE/mast cell axis
and IL-5/eosinophil axis.1 Interferon (IFN)-γ was used as
a parameter for the Th1-mediated immune response. The
biological properties of IL-6 include the induction of
acute-phase proteins, stimulation of hematopoietic stem
cell growth and thrombopoiesis.9 Increased IL-6 levels
precede hematologic recovery and correlate with pul-
monary complications after BMT.10 Except for IFN-γ, all
other Th2 cytokine levels were decreased with BMT and
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Table 1 Clinical parameters before and after bone marrow
transplantation in an asthmatic
Before BMT After BMT
(day –15) (day 98)
Pulmonary Function
VC 3.32 3.84
%VC 91.4 105.7
FVC (L) 3.33 3.52
FEV1 (L) 2.18 2.42
FEV1 % 65.4 68.7
%FEV1 72.1 80.1
PC20ACh (µg/mL) 900 480
Salbutamol-induced increase 0.55 0.65
in FEV1 (L)
Peripheral cytokines and IgE
IL-4 (pg/mL) 5.8 < 2.0
IL-5 (pg/mL) 52.4 < 5.0
IL-6 (pg/mL) 4.9 2.4
INF-γ (IU/mL) 0.2 0.3
IgE (IU/mL) 150 12
RAST (UA/mL) All negative All negative
BMT, Bone marrow transplantation; %VC, percent of vital capacity
normalized to the predicted value; FVC, forced vital capacity; FEV1,
forced expiratory volume in 1 s; FEV1%, percent of FEV1 normalized to
the predicted value; PC20ACh, the concentration of acetylcholine
needed to produce a 20% fall in FEV1; IL, interleukin; IFN, interferon;
radioallergosorbent test (RAST) to the following 16 common allergens:
Sweet vernal grass, Timothy, Common ragweed, Magworth, Japanese
cedar, Penicilium notatum, Cladsporium herbarum, Aspergillus fumiga-
tus, Alternaria alternata, Candida albicans, cat dander, dog epithelium,
Dermatophagoides farinae, Hollister-Stier Labs (House dust 2), egg
white and soya bean.
Fig. 2 Transverse section of an airway from the bone marrow
transplantation (BMT)-treated asthmatic at autopsy. The BMT-
treated asthmatic died from Pseudomonas aeruginosa pneu-
monia 200 days after BMT. Disrupted airway epithelium and
neutrophil infiltration are present, but goblet cell hyperplasia is
absent. It is difficult to evaluate the thickening of the basement
membrane, although mild smooth muscle hypertrophy (and/or
hyperplasia) is seen (hematoxylin–eosin stain; original magnifi-
cation ×80).
immunomodulators in combination (Table 1). This may
be the result of replacement of hematopoietic cells
rather than a simple effect of the non-specific immuno-
modulator tacrolimus because, despite the fact that
tacrolimus inhibits both Th1 and Th2 cells, INF-γ levels
did not change.3
Bone marrow transplantation from atopic donors
evokes newly developed asthma in two of 12 recipients.11
Indeed, AHR is transferable by T cells from asthma-like
hyperresponsive mice to non-asthma-like hyporesponsive
mice.12 In contrast, asthma may be a local disease,
because the lung transplanted from an asthmatic donor
developed asthma in a non-asthmatic recipient, but 
the lung from a non-asthmatic donor did not develop
asthma in an asthmatic recipient.13 Unfortunately, we
could not measure either airway sensitivity or plasma
cytokine profiles of the donor. Therefore, we cannot
exclude the possibility that bone marrow from the donor
may function in a similar manner to the original marrow.
In other words, the airway sensitivity of this patient may 
be reset at the donor’s level after BMT. Thus, theoretically,
it is possible that the second measurement of airway
sensitivity was the result of coincidentally introduced
AHR marrow. However, practically, this possibility is not
so high. The reasons are as follows:
1. The decreased plasma IL-4, IL-5, and IL-6 levels after
BMT (Table 1) suggest that the introduced marrow was
not sufficient for reconstitution of Th2 cytokine-predomi-
nant profile, resulting in the 10-fold lower plasma IgE
level than before BMT.
2. A recent twin study reported that AHR associations, as
measured by an odds ratio, were 14.1 and 4.2 in 183
monozygous twins and 198 dizygous twins, respectively.14
Based on this study, coincidental AHR marrow transplan-
tation may occur with a probability similar to or less than
that in the group of dizygous twins.
3. Even if the AHR-marrow was transplanted, the 
BMT-supporting therapy, including corticosteroids and
immunomodulators, effectively inhibited IL-4 and IL-5
production below detectable levels. The effectiveness of
the therapy was also supported by the low IL-6 level,
because acute GVHD induces IL-6 production.9,10
The main source of Th2 cytokines, including IL-4, IL-5
and IL-6, is hematopoietic cells and daily variability of
PEF correlates with the extent of AHR. Beclomethasone
dipropionate inhalation not only improved asthmatic
symptoms, but also decreased PEF variability in this
patient. This leads to an assumption that steroid-
sensitive, presumably Th2 cytokine-mediated, airway
inflammation was essential for the asthma symptoms
and deterioration of AHR further before BDP inhalation.
We hypothesize that AHR consisted of two components,
steroid sensitive and insensitive, and that the steroid-
insensitive component was independent of hematopoietic
cells in this patient. If so, the main component of the first
AHR (before BMT) would be steroid insensitive and
hematopoietic cell independent. Thus, it is reasonable
that, despite replacement of hematopoietic cells and
systemic administration of immunosuppressive agents in
combination, which restored the imbalance of Th1 and
Th2 cells, the second AHR did not change. Irreversible
airway remodeling before BMT may be another possible
reason for the unchanged AHR (Fig. 2). Thus, AHR and
airway inflammation may develop independently, at least
in part, but both needed to be present for an asthma
attack to be present in this patient. This interpretation
does not conflict with the current inflammation theory of
asthma. The profiles of airway structure cells, including
epithelial cells, fibroblasts, and smooth muscle cells, may
change to an asthmatic phenotype.4,15 Hence, although
control of inflammatory cells, such as lymphocytes, eosin-
ophils, mast cells, neutrophils and antigen-presenting
cells (e.g. alveolar macrophages and dendritic cells), was
definitely required for treatment of asthma, the inflamma-
tory cells may not be a sufficient target for the total reduc-
tion of AHR in this asthmatic.
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